TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03594721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marvel AM
Description: Study staff will perform each application of approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back at each of ten sequential visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marvel AM
Description: Study staff will perform each application of approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back at each of ten sequential visits.
Study: NCT03206983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cana's Ring
Description: The device is used during cataract surgery to help dilate small pupils (under 5mm)
Study: NCT04407286

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Oral vitamin D3 capsules
Study: NCT00659906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility Training
Description: 60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
Study: NCT02644694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate Ophthalmic Solution
Description: Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
Study: NCT00553618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin and Dacarbazine
Description: IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.~Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks.
Study: NCT02252328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 80mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily
Study: NCT03676465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CloudConnect Report
Description: Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. The participants will receive a weekly CloudConnect Report that is based on analysis of the data gathered from the downloads provided by the subject during that week. Participants will both receive weekly contact from the study team to discuss the communication that the subject \& their parent had during the week about the participant's diabetes management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Will not receive a CloudConnect Report
Description: Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. Participants will receive weekly contact from the study team to discuss the communication that the subject \& their parent had during the week about the participant's diabetes management.
Study: NCT04259346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC.
Study: NCT03021928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-To-Treatment Randomization
Description: The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 72 (+/- 24) hours, 132 (+/- 12) hours, 228 (+/- 12) hours, and 324 (+/- 12) hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-To-Treatment Randomization
Description: The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 72 (+/- 24) hours, 132 (+/- 12) hours, 228 (+/- 12) hours, and 324 (+/- 12) hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-To-Treatment Randomization
Description: The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 72 (+/- 24) hours, 132 (+/- 12) hours, 228 (+/- 12) hours, and 324 (+/- 12) hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-To-Treatment Randomization
Description: The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 72 (+/- 24) hours, 132 (+/- 12) hours, 228 (+/- 12) hours, and 324 (+/- 12) hours.
Study: NCT00832091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymosin Beta 4
Description: There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were three concentrations of gel used for topical administration to the active groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
Study: NCT01936428

Intervention type: OTHER
Group type: OTHER
Intervention: interview
Study: NCT03884127

Intervention type: DRUG
Intervention: Ezetimibe 10mg
Description: On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks

Intervention type: DRUG
Intervention: Orlistat 120 MG
Description: On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
Study: NCT03667573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS Dosage (A)
Description: mild electrical stimulation delivered to lumbosacral spinal cord

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS Dosage (A)
Description: mild electrical stimulation delivered to lumbosacral spinal cord

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS Dosage (B)
Description: mild electrical stimulation delivered to lumbosacral spinal cord

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS Dosage (B)
Description: mild electrical stimulation delivered to lumbosacral spinal cord

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: textured shoe insoles
Description: textured shoe insoles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: textured shoe insoles
Description: textured shoe insoles
Study: NCT00593775

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: assisted hatching
Description: assisted hatching with laser
Study: NCT02608294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: The patient is placed on a stretcher, his ankle positioned in plantar flexion and inversion, a measure was held between Point A and B with a tape measure, right after the KT was removed from the paper and cut to the same extent. The KT was pulled to its maximum limit and measured with a tape for a second evaluator. This measure found after the maximum tensile strain represented 100% and a rule of three was applied in order to find the 35% voltage for muscle activation. After finding the measure of 35% strain in centimeters, the evaluator cut KT this measurement and the same was discarded. Finally the tape was positioned at Point A; pulled up to Point B; and fixed. This procedure was carried out with the ankle positioned in plantar flexion and inversion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kinesio Taping Sham
Description: The sham group received the tape applied without tension. The patient was positioned supine; the ankle was placed in a neutral position (90 degrees); and measured between Point A and Point B with a tape measure placed on the skin was performed. Once registered this measure in centimeters the evaluator cut the KT with the same measure, but without the presence of paper attached to it to ensure that there was no tension, because the KT needs a minimum voltage to be applied on paper. After measured and cut the KT, it was applied to the patient in the supine position with the ankle positioned at 90 degrees with no traction.
Study: NCT01785290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg/q8h
Description: Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~* aged ≥ 80 years~* weight ≤ 50 kg~* liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg/q8h
Description: Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~* aged ≥ 80 years~* weight ≤ 50 kg~* liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9%
Study: NCT01698073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mCOL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AS+
Study: NCT00911066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:~* Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)~* Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)~* Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)~* Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)~* Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered (IV or subcutaneous (SC)) on Days 8 to 12 and Days 15 and 16 in Cycle 1, and on Days 1 to 5 and Days 8 to 9 (Schedule D)
Study: NCT02084875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib modified-release (MR) formulation
Description: A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib modified-release (MR) formulation
Description: tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.
Study: NCT01396031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Standard of care
Study: NCT06442085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teaching of trauma resuscitation by using virtual reality simulation
Description: The intervention was teaching of trauma resuscitation by using VRS. Following welcome and a video lecture by Advance Trauma Life Support certified physician, the intervention group participants were orientated (15 minutes) to the VRS environment, head-mounted display (Oculus Rift S or Oculus Quest, Oculus, USA) and hand controllers by playing game First Steps (Oculus, USA). Then the participants were training by using the Internal Hemorrhage scenario in Trauma Simulator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teaching of trauma resuscitation by using mannequin based simulation
Description: Volunteers were trained in groups of three or four by using mannequin-based rapid cycle deliberate practice simulation facilitated by a critical care physician. Next, the volunteers had 50 min training of the same trauma scenario as the intervention group. The simulation facility was set-up as close as possible to the virtual reality environment.
Study: NCT03570190

Intervention type: OTHER
Intervention: Coordinator
Description: A THV coordinator will be responsible for communication with the patients and the caregivers as well as for monitoring medical documentation and treatment pathways. The registry will consist of 3 phases:~* Determination of the status quo~* Dedicated reflection and training followed by implementation of tailored changes~* Determination of the effect
Study: NCT03696628

Intervention type: OTHER
Group type: OTHER
Intervention: Electrocardiogram
Description: heart testing

Intervention type: OTHER
Group type: OTHER
Intervention: Electrocardiogram
Description: heart testing

Intervention type: OTHER
Group type: OTHER
Intervention: physical examination
Description: done by the investigator

Intervention type: OTHER
Group type: OTHER
Intervention: physical examination
Description: done by the investigator

Intervention type: OTHER
Group type: OTHER
Intervention: echocardiography
Description: heart testing

Intervention type: OTHER
Group type: OTHER
Intervention: echocardiography
Description: heart testing

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test
Description: A sample of blood will be taken to each patient or healthy children in order to generate hiPSC-cardiomyocytes
Study: NCT05386069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NOMO Protocol
Description: Standard weight-based ketamine bolus (0.5 mg/kg) at procedure start, no Opioid rescue medications
Study: NCT03696628

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test
Description: A sample of blood will be taken to each patient or healthy children in order to generate hiPSC-cardiomyocytes
Study: NCT00004127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT02640014

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk
Description: Milk Oral immunotherapy
Study: NCT05742100

Intervention type: DRUG
Intervention: Darvadstrocel
Description: expanded allogeneic adipose-derived mesenchymal stem cell therapy for the treatment of complex perianal fistulas
Study: NCT03863054

Intervention type: DEVICE
Intervention: NATROX™ Topical Oxygen Therapy System
Description: A small battery-powered electrochemical oxygen generator to concentrate atmospheric oxygen and feed to wound site through a dressing-like oxygen distribution system
Study: NCT00797810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT02825940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.
Study: NCT00350909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief intervention (cognitive-behavioral therapy)
Description: Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: brief intervention (cognitive-behavioral therapy)
Description: Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).
Study: NCT02825940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered to participants with NSCLC at a dose of 1250 mg/m\^2 on Days 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered to participants with NSCLC at a dose of 75 mg/m\^2 on Day 1.
Study: NCT03890497

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: The inactivated poliovirus vaccine (IPV) developed by Salk was the first available polio vaccine licensed in 1955 in the United States. The current formulation of IPV got licensed in 1987 and has a higher potency than the original Salk IPV. Almost 100% of children two months of age or older who receive 2-3 doses of intramuscular (IM) IPV achieve high antibody levels against the all three serotypes. IPV (.5mL) can be administered subcutaneously (SC) or IM and fractional (0.1 ml) doses of IPV are generally administered intradermally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: The inactivated poliovirus vaccine (IPV) developed by Salk was the first available polio vaccine licensed in 1955 in the United States. The current formulation of IPV got licensed in 1987 and has a higher potency than the original Salk IPV. Almost 100% of children two months of age or older who receive 2-3 doses of intramuscular (IM) IPV achieve high antibody levels against the all three serotypes. IPV (.5mL) can be administered subcutaneously (SC) or IM and fractional (0.1 ml) doses of IPV are generally administered intradermally
Study: NCT02381067

Intervention type: OTHER
Group type: OTHER
Intervention: NuCel with Allograft Bone
Description: NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Allograft bone is bone that comes another patient. NuCel and Allograft bone will be combined for this treatment.
Study: NCT00614042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRU-016 (anti-CD37 protein therapeutic)
Description: TRU-016 administered via IV infusion weekly for 8 weeks and then monthly
Study: NCT03942549

Intervention type: DEVICE
Intervention: Retropubic midurethral sling
Description: Midurethral sling
Study: NCT01371175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA.HIVA
Description: 0.5mg DNA.HIVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA.HIVA
Description: 0.5mg DNA.HIVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA.HIVA
Description: 0.5mg DNA.HIVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA.HIVA
Description: 0.5mg DNA.HIVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA.HIVA
Description: 0.5mg DNA.HIVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA.HIVA
Description: 0.5mg DNA.HIVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA.HIVA
Description: 0.5mg DNA.HIVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA.HIVA
Description: 0.5mg DNA.HIVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA.HIVA
Description: 0.5mg DNA.HIVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 5x10\^6 pfu MVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 5x10\^6 pfu MVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 5x10\^7 pfu MVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 5x10\^7 pfu MVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 5x10\^7 pfu MVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 5x10\^7 pfu MVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 2.5x10\^8 pfu MVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 2.5x10\^8 pfu MVA or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVA
Description: 2.5x10\^8 pfu MVA or placebo
Study: NCT00052689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV